How does fingolimod (Gilenyal fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

被引：19

作者：

Fazekas, Franz ^{[1
]}

Bajenaru, Ovidiu ^{[2
]}

Berger, Thomas ^{[3
]}

Fabjan, Tanja Hojs ^{[4
]}

Ledinek, Alenka Horvat ^{[5
]}

Jakab, Gabor ^{[6
]}

Komoly, Samuel ^{[7
]}

Kobys, Tetiana ^{[8
]}

Kraus, Joerg ^{[9
]}

Kurca, Egon ^{[10
]}

Kyriakides, Theodoros ^{[11
]}

Lisy, L'ubomir ^{[12
]}

Milanov, Ivan ^{[13
]}

Nehrych, Tetyana ^{[14
]}

Moskovko, Sergii ^{[15
]}

Panayiotou, Panayiotis ^{[16
]}

Jazbec, Sasa Sega ^{[17
]}

Sokolova, Larysa ^{[18
]}

Talab, Radomir ^{[19
]}

Traykov, Latchezar ^{[20
]}

Turcani, Peter ^{[21
]}

Vass, Karl ^{[22
]}

Vella, Norbert ^{[23
]}

Voloshyna, Nataliya ^{[24
]}

Havrdova, Eva ^{[25
]}

机构：

[1] Med Univ Graz, Dept Neurol, Graz, Austria

[2] Univ Med & Pharm Carol Davila, Dept Neurol Neurosurg & Psychiat, Bucharest, Romania

[3] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria

[4] Univ Med Ctr Maribor, Dept Neurol, Maribor, Slovenia

[5] Univ Med Ctr Ljubljana, Dept Neurol, Ljubljana, Slovenia

[6] Uzsoki Hosp, Dept Neurol, Budapest, Hungary

[7] Univ Pecs, Dept Neurol, Pecs, Hungary

[8] MS Hosp, Kiev, Ukraine

[9] Paracelsus Med Univ, Salzburger Landeskliniken, Dept Neurol, A-5020 Salzburg, Austria

[10] Univ Hosp, Dept Neurol, Martin, TN, Slovakia

[11] Cyprus Inst Neurol & Genet, Neuropathol Lab, Clin A, Cyprus Sch Mol Med, Nicosia, Cyprus

[12] Univ Hosp Bratislava, Ruzinov Hosp, Dept Neurol, Bratislava, Slovakia

[13] Univ Hosp St Naum, Neurol Clin, Sofia, Bulgaria

[14] Natl Med Univ, Dept Neurol, Lvov, Ukraine

[15] Natl Med Univ, Dept Neurol, Vinnytsya, Ukraine

[16] Aretaieio Private Hosp, Nicosia, Cyprus

[17] Univ Med Ctr Ljubljana, Dept Neurol, Ljubljana, Slovenia

[18] Natl Med Univ, Dept Neurol, Kiev, Ukraine

[19] Hradec Kralove Hosp, Dept Neurol, Hradec Kralove, Czech Republic

[20] Univ Hosp Alexandrovska, Neurol Clin, Sofia, Bulgaria

[21] Comenius Univ, Dept Neurol, Bratislava, Slovakia

[22] Med Univ Vienna, Dept Neurol, Vienna, Austria

[23] Mater Dei Hosp Tal Oroqq, Dept Neurol, Msida, Malta

[24] AMS Ukraine, Inst Neurol Psychiat & Narcol, Dept Neuroinfect, Kharkov, Ukraine

[25] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

来源：

FRONTIERS IN NEUROLOGY | 2013年 / 4卷

关键词：

multiple sclerosis; fingolimod; treatment; algorithm; expert opinion; ORAL FINGOLIMOD; FTY720; RECEPTORS; THERAPY; SPHINGOSINE-1-PHOSPHATE; DISEASE;

D O I：

10.3389/fneur.2013.00010

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya6) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naive patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients.

引用

页数：14

共 31 条

[1] Fingolimod is a potential novel therapy for multiple sclerosis [J].